Orgenesis Inc. (ORGS)
USD 2.4
(10.6%)
USD 2.4
(10.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -60.71 Million USD | -683.59% |
| 2022 | -8.3 Million USD | 50.17% |
| 2021 | -15.71 Million USD | 85.46% |
| 2020 | -94.2 Million USD | -356.34% |
| 2019 | -18.9 Million USD | -70.81% |
| 2018 | -12.39 Million USD | -19.9% |
| 2017 | -9.84 Million USD | -17.28% |
| 2016 | -9.04 Million USD | -66.38% |
| 2015 | -2.64 Million USD | -4.85% |
| 2014 | -4.79 Million USD | 8.86% |
| 2013 | -5.35 Million USD | -9.54% |
| 2012 | -4.99 Million USD | -6792.9% |
| 2011 | -72.35 Thousand USD | -1072.07% |
| 2010 | -6173.00 USD | 75.93% |
| 2009 | -25.64 Thousand USD | -632.8% |
| 2008 | -3500.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -8.49 Million USD | -43.35% |
| 2024 Q2 | -3.36 Million USD | 8.97% |
| 2023 Q3 | -2.08 Million USD | 23.71% |
| 2023 Q1 | -2.62 Million USD | -428.09% |
| 2023 FY | - USD | -683.59% |
| 2023 Q2 | -2.72 Million USD | -3.84% |
| 2023 Q4 | -37.14 Million USD | -1684.2% |
| 2022 Q1 | -3.31 Million USD | 30.11% |
| 2022 FY | - USD | 50.17% |
| 2022 Q4 | 801 Thousand USD | 288.83% |
| 2022 Q3 | 206 Thousand USD | 104.49% |
| 2022 Q2 | -4.59 Million USD | -38.52% |
| 2021 Q4 | -4.74 Million USD | 34.2% |
| 2021 Q1 | 595 Thousand USD | 101.14% |
| 2021 FY | - USD | 85.46% |
| 2021 Q3 | -7.2 Million USD | -289.41% |
| 2021 Q2 | -1.85 Million USD | -411.09% |
| 2020 Q2 | -26.43 Million USD | -334.21% |
| 2020 Q1 | -6.08 Million USD | -9.08% |
| 2020 Q3 | -9.01 Million USD | 65.92% |
| 2020 Q4 | -52.34 Million USD | -480.93% |
| 2020 FY | - USD | -356.34% |
| 2019 Q3 | -3.64 Million USD | 15.25% |
| 2019 Q1 | -7.34 Million USD | -13.15% |
| 2019 Q2 | -4.29 Million USD | 41.53% |
| 2019 FY | - USD | -70.81% |
| 2019 Q4 | -5.58 Million USD | -53.35% |
| 2018 Q2 | -2.09 Million USD | 21.8% |
| 2018 FY | - USD | -19.9% |
| 2018 Q3 | -1.08 Million USD | 48.24% |
| 2018 Q4 | -6.49 Million USD | -497.79% |
| 2018 Q1 | -2.68 Million USD | -129.91% |
| 2017 Q3 | -2.62 Million USD | 9.64% |
| 2017 Q4 | -1.16 Million USD | 55.54% |
| 2017 FY | - USD | -17.28% |
| 2017 Q2 | -2.9 Million USD | 60.95% |
| 2017 Q1 | -7.43 Million USD | -230.04% |
| 2016 FY | - USD | -66.38% |
| 2016 Q4 | -2.25 Million USD | -22.17% |
| 2016 Q3 | -1.84 Million USD | 43.73% |
| 2016 Q2 | -3.27 Million USD | -170.1% |
| 2016 Q1 | -1.21 Million USD | 20.45% |
| 2015 Q2 | -1.44 Million USD | -72.13% |
| 2015 Q3 | -1.41 Million USD | 1.71% |
| 2015 FY | - USD | -4.85% |
| 2015 Q4 | -1.52 Million USD | -7.77% |
| 2015 Q1 | -837.02 Thousand USD | 4.25% |
| 2014 Q1 | -1.11 Million USD | 29.74% |
| 2014 Q4 | -874.14 Thousand USD | 32.05% |
| 2014 FY | - USD | 8.86% |
| 2014 Q3 | -1.28 Million USD | 24.34% |
| 2014 Q2 | -1.7 Million USD | -52.11% |
| 2013 Q3 | -1.16 Million USD | 10.08% |
| 2013 Q1 | -1.31 Million USD | 3.71% |
| 2013 FY | - USD | -9.54% |
| 2013 Q4 | -1.59 Million USD | -36.99% |
| 2013 Q2 | -1.29 Million USD | 2.12% |
| 2012 FY | - USD | -6792.9% |
| 2012 Q4 | -1.37 Million USD | 27.44% |
| 2012 Q3 | -1.88 Million USD | -115.87% |
| 2012 Q2 | -874.82 Thousand USD | -2.48% |
| 2012 Q1 | -853.66 Thousand USD | -1278.74% |
| 2011 Q1 | -5436.00 USD | 31.98% |
| 2011 FY | - USD | -1072.07% |
| 2011 Q4 | -61.91 Thousand USD | -2163.84% |
| 2011 Q3 | -2735.00 USD | -20.75% |
| 2011 Q2 | -2265.00 USD | 58.33% |
| 2010 Q4 | -7992.00 USD | -44.99% |
| 2010 Q3 | -5512.00 USD | -12.72% |
| 2010 FY | - USD | 75.93% |
| 2010 Q2 | -4890.00 USD | -75.96% |
| 2010 Q1 | -2779.00 USD | 45.14% |
| 2009 Q1 | -1706.00 USD | 0.0% |
| 2009 Q4 | -5066.00 USD | 62.16% |
| 2009 Q3 | -13.38 Thousand USD | -144.06% |
| 2009 FY | - USD | -632.8% |
| 2009 Q2 | -5486.00 USD | -221.57% |
| 2008 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -13474.578% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -105.782% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 46.764% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -285.242% |
| Better Therapeutics, Inc. | -38.26 Million USD | -58.69% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -58.678% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -239.461% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -79.996% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -81.937% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 42.905% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -6546.94% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -86.928% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -30.039% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -968.274% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -272.476% |
| Molecular Templates, Inc. | 1.43 Million USD | 4346.014% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -337.604% |
| NexImmune, Inc. | -28.16 Million USD | -115.56% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -18.373% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -82604.043% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -276.073% |
| Scopus BioPharma Inc. | -11.71 Million USD | -418.375% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 88.754% |
| Statera Biopharma, Inc. | 38.93 Million USD | 255.947% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -782.016% |
| Trevena, Inc. | -35.28 Million USD | -72.064% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -108226.346% |
| Vaccinex, Inc. | -19.74 Million USD | -207.464% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -5699.358% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -29.568% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -735.989% |